Skip to main content
European Commission logo
Deutsch Deutsch
CORDIS - Forschungsergebnisse der EU
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

Ultra-small Nanohybrides for Advanced Theranostics

Projektbeschreibung

Extrem klein und vielseitig talentiert: Nanohybridmaterialien für Diagnose und Therapie

Nanomaterialien sind aufgrund ihrer winzigen Durchdringungsgrößen und ihrer einzigartigen funktionellen Eigenschaften als Wegbereiter für kombinierte diagnostisch-therapeutische Technologien ins Rampenlicht gerückt. Nanohybride, die sowohl organische als auch anorganische Komponenten, einschließlich metallischer Bestandteile, enthalten, bieten enorme Möglichkeiten für die Funktionalisierung biologischer oder bioaktiver Moleküle. Das EU-finanzierte Projekt UNAT wird daher das Leistungsvermögen von Metall-Kohlenstoff-Nanohybriden für die multimodale In-vivo-Bildgebung und -Tumortherapie mittels elektromagnetischer Strahlung untersuchen. Dabei sollen die Diagnose und Therapie von Krebs im Rahmen einer ehrgeizigen Kampagne durch präklinische In-vitro- und In-vivo-Experimente evaluiert werden.

Ziel

Nowadays, research focusing on control and use of nanomaterials in different areas including life sciences has become a key driver of innovation. UNAT project aims at a systematic interdisciplinary study of metal-carbon nanohybrides (NHs) for advanced theranostic application. Indeed, development of NHs based on organic & inorganic moieties can synergistically or antagonistically influence functional properties of engineered nanotheranostic medicines. UNAT will develop innovative approaches for synthesis and multi-functional application of ultra-small (<10 nm) carbon-based NHs functionalized with various metal atoms for diagnostics and therapy of cancer. In particular, carbon cores of NHs will be chemically synthesized from biomasses and bio-wastes. The combination of pre-clinical in-vitro & in-vivo experiments will allow to evaluate theranostic potential of the NHs.
UNAT will associate an industrial partner from Greece (Bioemtech), a research and innovation center from Ukraine (Science Park) and 2 academic research groups from France (UCBL) and Italy (CNR). The uptake efficiency and specific localization of the NHs in biological cells depending on their intentionally designed surface chemistry will be studied in details. Extremely rich physico-chemical properties of the NHs will allow their application as universal multi-modal (MRI, PET, X-ray, Fluorescence, Photoacoustic) in-vivo bio-imaging agents. The multimodal imaging strategy will allow us to correlate the images obtained with the use of various imaging facilities to increase general reliability of visualization of the NHs localization in tumours. Various exciting electro-magnetic sources used for medical purposes will be simultaneously used for therapy of cancer tissues containing the incorporated NHs. Strongly complementary research experiences of the partners involved in UNAT and a high degree of cooperative integration between them will allow a deep scientific study of the theranostic potential of the NHs.

Koordinator

UNIVERSITE LYON 1 CLAUDE BERNARD
Netto-EU-Beitrag
€ 142 600,00
Adresse
BOULEVARD DU 11 NOVEMBRE 1918 NUM43
69622 Villeurbanne Cedex
Frankreich

Auf der Karte ansehen

Region
Auvergne-Rhône-Alpes Rhône-Alpes Rhône
Aktivitätstyp
Higher or Secondary Education Establishments
Links
Gesamtkosten
€ 142 600,00

Beteiligte (4)